The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

Investment Considerations CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP)”

View Profile